FLT3 and acute myeloid leukemia: Emerging case reports also underscore the complex interplay between prior intensive therapies, clonal hematopoiesis, and the emergence of secondary AML harboring FLT3-ITD mutations following CAR-T exposure, emphasizing the need for long-term hematopoietic monitoring (121).